Femasys FEMY 深 沪
等待开盘 10-08 09:30:00 美东时间
2.00
-0.080
-3.85%
华盛通- 最 高2.049
- 今 开2.04
- 成交量 5.60万股
- 最 低 1.96
- 昨 收 2.08
- 总市值 1675.01万
- 52周最高 22.20
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 1.96
- 委 比 0.00%
- 总股本 837.50万
- 历史最高 275.00
- 量 比 0.49
- 振 幅 4.28%
- 历史最低 1.96
- 每 手 1
- 风险率 4.99%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Femasys Partners with CapexMD to Expand Patient Access to FemaSeed® Fertility Portfolio
Femasys Inc. has partnered with CapexMD to enhance patient access to its fertility solutions, including FemaSeed Complete and diagnostic tools, through dedicated financing. This collaboration aims to reduce financial barriers, making fertility care more affordable and accessible for patients across OB/GYN practices and fertility centers.
09-09 13:00
Femasys shares are trading higher after the company announced that the U.S. Food and Drug Administration has approved the company’s modular premarket approval application pathway for FemBloc.
Femasys shares are trading higher after the company announced that the U.S. Food and Drug Administration has approved the company’s modular premarket approval application pathway for FemBloc.
08-19 22:29
美股大行评级 | 富国上调闪迪目标价从1400美元升至1550美元；塔吉特、Workday、应用材料等获多家大行上调目标价
今日重点评级关注：富瑞：维持ProMIS Neurosciences"买入"评级，目标价从69美元升至100美元；Benchmark：维持Cineverse"买入"评级，目标价从12美元升至14美元
08-17 13:37
Femasys Q2 EPS $(1.08) Beats $(1.33) Estimate, Sales $756.716K Beat $730.667K Estimate
Femasys (NASDAQ:FEMY) reported quarterly losses of $(1.08) per share which beat the analyst consensus estimate of $(1.33) by 18.8 percent. This is a 66.25 percent increase over losses of $(3.20) per share from the same period last year. The company reported quarterly sales of $756.716 thousand which...
08-15 04:15
Maxim Group Maintains Buy on Femasys, Lowers Price Target to $10
Maxim Group analyst Jason McCarthy maintains Femasys (NASDAQ:FEMY) with a Buy and lowers the price target from $30 to $10.
08-15 04:15
Femasys completes $30 million private placement financing
The latest announcement is out from Femasys ( ($FEMY) ). On August 7, 2026, Fem...
08-12 05:22
Femasys Announces $30M Private Placement Led By New Investors And Members Of Management
Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announced today that it has entered into a securities purc...
08-07 21:32
Femasys Secures $30 Million Private Placement, with Potential Proceeds of Up to $90 Million
Femasys Inc. announced a $30 million private placement with accredited investors, led by Nantahala Capital, to strengthen its balance sheet and advance its fertility and non-surgical birth control solutions. The offering includes shares and warrants, with potential additional proceeds of up to $60 million if all warrants are exercised. The company aims to expand access to its innovative products and improve healthcare outcomes for women worldwide...
08-07 13:25
Femasys Announces CE Mark Approval For FemHSG Catheter, Further Expanding Its Portfolio In Europe Through Commercial Partners
Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide, announced today CE Mark approval for
05-13 21:05
